An Open-Label, Single-Arm, Historically Controlled, Prospective, Multi-Center Phase III Study to Evaluate the Pharmacokinetics and Safety of Immune Globulin Intravenous (Human) GC5107 in Pediatric Subjects With Primary Humoral Immunodeficiency

The purpose of this study is to evaluate the pharmacokinetics and safety of Immune Globulin Intravenous (Human) GC5107 in pediatric subjects with Primary Humoral Immunodeficiency (PHID).

开始日期2020-12-21

申办/合作机构

GC Biopharma Corp.

[+1]

NCT03896932

/ CompletedN/AIIT

Study of Safety and Efficacy of Mini-pool Intravenous Immunoglobulin (MP-IVIG) Prepared by Assiut University Hospital Blood Bank in Primary Immunodeficiency Patients

1. study the pharmacokinetics of mini-pooled intravenous immunoglobulin( MP-IVIG)
2. Study the safety and efficacy of a newly developed preparation of MP-IVIG in children with primary immunodeficiency (PID) :
* Adverse reaction of MP-IVIG(anaphylaxis and haemolysis)( no or mild or moderate)
* Prevention of severe bacterial infection
* Improvement of general health(weight gain and mentality)
* Integration in to social live
3. Compare the efficacy of MP-IVIG to standard IVIG in children with primary immunodeficiency (PID).

开始日期2020-01-01

申办/合作机构

Assiut University

NCT03492710

/ Withdrawn临床3期

Phase III Study of Immune Globulin Intravenous (Human) IGIV-SN in Pediatric Subjects With Primary Humoral Immunodeficiency

To assess the safety, efficacy, and pharmacokinetics of IGIV-SN in pediatric subjects with primary immunodeficiency humoral diseases (PHID)

开始日期2019-04-30

申办/合作机构

Green Cross Co., Ltd.

100 项与 Immune globulin (GC Pharma) 相关的临床结果

登录后查看更多信息

100 项与 Immune globulin (GC Pharma) 相关的转化医学

登录后查看更多信息

100 项与 Immune globulin (GC Pharma) 相关的专利（医药）

登录后查看更多信息

257

项与 Immune globulin (GC Pharma) 相关的文献（医药）

2025-04-01·EUROPEAN JOURNAL OF NEUROLOGY

The Results of ADVANCE‐CIDP IVIG Trial: Intravenous Immunoglobulin 10% Therapy With GAMMAGARD LIQUID/Kiovig for Treatment of Relapse in Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Article

作者: Greco, Erin ; Sivakumar, K. ; Levine, Todd ; Wood, Jamie ; Duff, Kim ; Dori, Amir ; Solano, Juan Marcos ; Anderson‐Smits, Colin ; Marchioni, Enrico ; Gamez, Josep ; Rejdak, Konrad ; Pasnoor, Mamatha ; Li, Zhaoyang ; Casasnovas, Carlos ; Corbo, Massimo ; Hasan, Shabbir ; Ay, Hakan ; Chroni, Elisabeth ; Bril, Vera ; Schmidt, Jens ; Cocito, Dario ; Rivero, Alberto ; Siciliano, Gabriele

ABSTRACT:

Background:

ADVANCE‐CIDP IVIG evaluated the efficacy and safety of immune globulin infusion (human) 10% solution (IVIG 10%; GAMMAGARD LIQUID, also known as Kiovig) in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) as a rescue treatment for patients relapsing during the ADVANCE‐CIDP 1 trial.

Methods:

Open‐label ADVANCE‐CIDP IVIG included adult patients with confirmed CIDP relapse (≥ 1‐point increase in adjusted Inflammatory Neuropathy Cause and Treatment [INCAT] disability scores from pre‐treatment baseline) during ADVANCE‐CIDP 1, which assessed the efficacy and safety of hyaluronidase‐facilitated subcutaneous immunoglobulin (fSCIG) 10%. Patients received an induction IVIG 10% dose (2 g/kg) followed by maintenance infusions at the same monthly equivalent dose of pre‐randomization IVIG, 3‐weekly for 6 months. The primary outcome was the responder rate (≥ 1‐point decrease in adjusted INCAT scores at treatment cessation vs. pre‐IVIG 10% baseline, in patients receiving placebo in ADVANCE‐CIDP 1). Other outcomes included the responder rate across all patients relapsing on fSCIG 10% or placebo in ADVANCE‐CIDP 1, time to functional improvement (≥ 1‐point decrease in adjusted INCAT score), and change in adjusted INCAT scores and Rasch‐built Overall Disability Scale (R‐ODS) centile scores from pre‐IVIG 10% baseline.

Results:

Overall, 20 patients received IVIG 10% (n = 4 [fSCIG 10%‐relapse group]; n = 16 [placebo‐relapse group]). Responder rate (95% confidence interval) was 100.0% (80.6%–100.0%) in the placebo‐relapse group and 95.0% (76.4%–99.1%) in the overall‐relapse population. Across all patients, median time to functional improvement was 25 days. At treatment cessation, mean changes from pre‐IVIG 10% baseline in adjusted INCAT and R‐ODS centile scores were −1.9 and 12.9, respectively.

Conclusions:

IVIG 10% effectively treated CIDP relapse and improved functional abilities.

2025-03-01·JOURNAL OF PHARMACEUTICAL SCIENCES

Developing ultra-high concentration formulations of human immune globulins for subcutaneous injectables

Article

作者: André, Guillaume ; Civati, Francesco ; Trout, Bernhardt L ; Ma, Wenchuan ; Yadav, Jayprakash ; Myerson, Allan S ; Liebminger, Andreas ; Teschner, Wolfgang ; Uddin, Shihab ; Braatz, Richard D

This work describes the first development of high-concentration suspension formulations of human immune globulin. Colloidal-level dispersions of immune globulin were achieved by suspending a spray dried solid powder of protein in a protein solution made saturated by the addition of pharmaceutical excipients. The spray drying process was used to generate ∼90 % of particles below 20μ. The monomer and aggregates content of immunoglobulin were found to be 93 % and 0.3 %, respectively. The injection forces for the colloidal suspensions were characterized using a dynamic compression test. The concentrations of 300, 380, and 400 mg/mL formulations were injected at 3.8 N, 10 N, and 16.5 N of maximum injection forces, respectively, when a 24-gauge needle was used. The viscosity of a 300 mg/mL suspension was 128 cP. The viscosity of a 380 mg/mL suspension was 284 cP, and the viscosity was higher for the 400 mg/mL formulation; however, injectability was not an issue, which remains rare for non-Newtonian, shear-thickening systems. It is acknowledged that the 400 mg/mL suspension formulation remained relatively challenging as compared to other suspensions for injection because of its very high viscosity, and significant force was required to inject it. We show that where ultra-high-concentration immune globulin is being developed within reasonable constraints of pharmaceutical regulation, with an injectability parameter, formulations might make their way to the clinic when viscosity could say otherwise. However, further work should be conducted to assess chemical stability (using methods such as mass spectrometry) along with forced degradation studies prior any clinical use.

2024-08-01·JHEP Reports

Proportion of pregnant women with HBV infection eligible for antiviral prophylaxis to prevent vertical transmission: A systematic review and meta-analysis

Article

作者: Ishii-Rousseau, Julian Euma ; Shimakawa, Yusuke ; Rao, Adya ; Delamare, Hugues ; Ségéral, Olivier ; Cresta, Mélanie ; Nayagam, Shevanthi ; Vincent, Jeanne Perpétue

Background & Aims:

In 2020, the World Health Organization (WHO) recommended peripartum antiviral prophylaxis (PAP) for pregnant women infected with hepatitis B virus (HBV) with high viremia (≥200,000 IU/ml). Hepatitis B e antigen (HBeAg) was also recommended as an alternative when HBV DNA is unavailable. To inform policymaking and guide the implementation of prevention of mother-to-child transmission strategies, we conducted a systematic review and meta-analysis to estimate the proportion of HBV-infected pregnant women eligible for PAP at global and regional levels.

Methods:

We searched PubMed, EMBASE, Scopus, and CENTRAL for studies involving HBV-infected pregnant women. We extracted proportions of women with high viremia (≥200,000 IU/ml), proportions of women with positive HBeAg, proportions of women cross-stratified based on HBV DNA and HBeAg, and the risk of child infection in these maternal groups. Proportions were pooled using random-effects meta-analysis.

Results:

Of 6,999 articles, 131 studies involving 71,712 HBV-infected pregnant women were included. The number of studies per WHO region was 66 (Western Pacific), 21 (Europe), 17 (Africa), 11 (Americas), nine (Eastern Mediterranean), and seven (South-East Asia). The overall pooled proportion of high viremia was 21.27% (95% CI 17.77-25.26%), with significant regional variation: Western Pacific (31.56%), Americas (23.06%), Southeast Asia (15.62%), Africa (12.45%), Europe (9.98%), and Eastern Mediterranean (7.81%). HBeAg positivity showed similar regional variation. After cross-stratification, the proportions of high viremia and positive HBeAg, high viremia and negative HBeAg, low viremia and positive HBeAg, and low viremia and negative HBeAg were 15.24% (95% CI 11.12-20.53%), 2.70% (95% CI 1.88-3.86%), 3.69% (95% CI 2.86-4.75%), and 75.59% (95% CI 69.15-81.05%), respectively. The corresponding risks of child infection following birth dose vaccination without immune globulin and PAP were 14.86% (95% CI 8.43-24.88%), 6.94% (95% CI 2.92-15.62%), 7.14% (95% CI 1.00-37.03%), and 0.14% (95% CI 0.02-1.00%).

Conclusions:

Approximately 20% of HBV-infected pregnant women are eligible for PAP. Given significant regional variations, each country should tailor strategies for HBsAg screening, risk stratification, and PAP in routine antenatal care.

Impact and implications:

In 2020, the WHO recommended that pregnant women who test positive for the hepatitis B surface antigen (HBsAg) undergo HBV DNA testing or HBeAg and those with high viremia (≥200,000 IU/ml) or positive HBeAg receive PAP. To effectively implement new HBV PMTCT interventions and integrate HBV screening, risk stratification, and antiviral prophylaxis into routine antenatal care services, estimating the proportion of HBV-infected pregnant women eligible for PAP is critical. In this systematic review and meta-analysis, we found that approximately one-fifth of HBV-infected pregnant women are eligible for PAP based on HBV DNA testing, and a similar proportion is eligible based on HBeAg testing. Owing to substantial regional variations in eligibility proportions and the availability and costs of different tests, it is vital for each country to optimize strategies that integrate HBV screening, risk stratification, and PAP into routine antenatal care services.

Systematic review registration:

This study was registered with PROSPERO (Protocol No: CRD42021266545).

项与 Immune globulin (GC Pharma) 相关的新闻（医药）

2025-12-23

·PRNewswire

GC Biopharma Secures IND Approval for Phase 1 Clinical Trial of COVID-19 mRNA Vaccine in Korea

- Phase 2 IND submission targeted for the second half of 2026 - Demonstrating the competitiveness of GC Biopharma's mRNA platform YONGIN, South Korea, Dec. 22, 2025 /PRNewswire/ -- GC Biopharma (006280.KS), a leading global biopharmaceutical company, announced today that Ministry of Food and Drug Safety (MFDS) in South Korea has approved the Investigational New Drug (IND) application for the Phase 1 clinical trial of "GC4006A", mRNA (messenger RNA) vaccine candidate for COVID-19. Following the IND submission in September, the approval was granted in a short timeframe. The company expects to accelerate development in alignment with the Korean government's policy initiative to localize mRNA vaccine. GC Biopharma plans to submit Phase 2 IND in the second half of 2026. GC4006A is a COVID-19 vaccine candidate developed using GC Biopharma's proprietary mRNA-LNP (Lipid Nanoparticle) platform. mRNA vaccines are regarded as a critical technology that extends beyond a single infectious disease, as they enable rapid responses to emerging pathogens and viral variants in future pandemics. Meanwhile, GC Biopharma was recently selected as a recipient of Phase 1 clinical research support under the Korea Disease Control and Prevention Agency (KDCA)'s 'mRNA Vaccine Development Support Project for Pandemic Preparedness'. "This IND approval represents a meaningful milestone, demonstrating the robustness and competitiveness of our mRNA platform", said Jaewoo Lee, Head of the Regulatory Science & Product Development Division at GC Biopharma. "We will continue to explore the applicability of the platform technology across various therapeutic areas, including vaccines." GC Biopharma's mRNA-LNP platform enhances both the level and durability of protein expression by applying its proprietary UTR1) patents, codon2) optimization technology, and LNP with advanced delivery efficiency. GC Biopharma is the first company in Korea to independently execute the entire process of mRNA vaccines from candidate discovery to manufacturing and production. --- 1) Untranslated Region, Regions positioned before and after the codon that play a role in controlling mRNA stability and protein expression 2) The portion of mRNA to produce proteins About GC Biopharma GC Biopharma (formerly known as Green Cross Corporation) is a biopharmaceutical company headquartered in Yong-in, South Korea. The company has over half a century of experience in the development and manufacturing of plasma derivatives and vaccines, and is expanding its global presence with successful US market entry of Alyglo® (intravenous immunoglobulin G) in 2024. In line with its mission to meet the demands of future healthcare, GC Biopharma continues to drive innovation by leveraging its core R&D capabilities in engineering of proteins, mRNAs, and lipid nanoparticle (LNP) drug delivery platform to develop therapeutics for the field of rare disease as well as I&I (Immunology & Inflammation). To learn more about the company, visit This press release may contain biopharmaceuticals in forward-looking statements, which express the current beliefs and expectations of GC Biopharma's management. Such statements do not represent any guarantee by GC Biopharma or its management of future performance and involve known and unknown risks, uncertainties, and other factors. GC Biopharma undertakes no obligation to update or revise any forward-looking statement contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. GC Biopharma Contacts (Media) Sohee Kim [email protected] Yelin Jun [email protected] Yoonjae Na [email protected] SOURCE GC Biopharma 21% more press release views with Request a Demo

疫苗临床申请信使RNA临床1期

2025-12-09

·动脉网

GC生物制药公司运送了世界上第一种重组炭疽疫苗“BARYTHRAX inj.”的首批剂量GC Biopharma Ships First Doses of World's First Recombinant Anthrax Vaccine, 'BARYTHRAX inj.'

GC Biopharma (006280.KS), a leading global biopharmaceutical company, today announced the first shipment of BARYTHRAX inj., the world's first recombinant anthrax vaccine. The product, jointly developed by the Korea Disease Control and Prevention Agency (KDCA) and GC Biopharma, was granted regulatory approval in April as Korea's 39th locally developed new drug.. GC Biopharma（006280.KS），一家全球领先的生物制药公司，今天宣布了世界上首个重组炭疽疫苗BARYTHRAX inj.的首次发货。该产品由韩国疾病控制与预防中心（KDCA）和GC Biopharma共同开发，于今年四月获得监管批准，成为韩国第39种本土研发的新药。The initial supply will be delivered to the KDCA for national stockpiling, supporting public health preparedness against biological threats, including potential bioterrorism. 初始供应将交付给韩国疾病控制与预防中心（KDCA），用于国家战略储备，以支持针对包括潜在生物恐怖主义在内的生物威胁的公共卫生防范工作。BARYTHRAX inj. is the first anthrax vaccine globally to be developed using recombinant protein technology. Unlike conventional vaccines that use live attenuated or avirulent strain of Bacillus anthracis, BARYTHRAX inj. is based solely on the purified Protective Antigen (PA) protein, a principal component of the anthrax toxin.. BARYTHRAX注射剂是全球首个采用重组蛋白技术开发的炭疽疫苗。与使用减毒或无毒炭疽芽孢杆菌株的传统疫苗不同，BARYTHRAX注射剂仅基于纯化的保护性抗原（PA）蛋白，这是炭疽毒素的主要成分。Clinical studies showed that BARYTHRAX inj. induces neutralizing antibodies that meet the predefined immunogenicity thresholds. This result supports its potential to effectively protect individuals in the event of anthrax exposure. 临床研究表明，BARYTHRAX注射剂能够诱导达到预定义免疫原性阈值的中和抗体。这一结果支持了它在炭疽暴露情况下有效保护个体的潜力。Furthermore, the safety assessment confirmed that the primary adverse events reported in the BARYTHRAX inj. group —such as injection-site pain, myalgia, and fatigue —were generally mild and temporary. No acute adverse reactions or deaths occurred, proving the vaccine's strong safety profile. 此外，安全性评估确认，BARYTHRAX注射组报告的主要不良事件（如注射部位疼痛、肌肉痛和疲劳）通常为轻度且短暂。未发生急性不良反应或死亡事件，证明了该疫苗良好的安全性。Manufacturing is carried out at GC Biopharma's advanced Hwasun facility in Korea, which can produce up to 10 million doses annually sufficient to immunize approximately 2.5 million people based on a four-dose regimen. The vaccine is also designed for rapid, scalable production in emergency scenarios.. 制造是在韩国GC Biopharma先进的和顺工厂进行的，该工厂每年可生产多达1000万剂疫苗，按照四剂方案足以免疫大约250万人。该疫苗还设计用于在紧急情况下快速、可扩展的生产。'Delivering the world's first recombinant anthrax vaccine marks a significant step forward in national biosecurity,' said Eun-Chul Huh, CEO of GC Biopharma. 'We remain committed to supporting national biodefense and advancing vaccine security through innovation and strategic partnerships.' “交付世界上首个重组炭疽疫苗标志着国家生物安全向前迈出了重要一步，”GC Biopharma首席执行官Eun-Chul Huh表示。“我们仍然致力于通过创新和战略合作伙伴关系来支持国家生物防御并提升疫苗安全性。”About GC Biopharma 关于GC BiopharmaGC Biopharma (formerly known as Green Cross Corporation) is a biopharmaceutical company headquartered in Yong-in, South Korea. The company has over half a century of experience in the development and manufacturing of plasma derivatives and vaccines, and is expanding its global presence with successful US market entry of Alyglo® (intravenous immunoglobulin G) in 2024. GC Biopharma（前身为Green Cross Corporation）是一家总部位于韩国龙仁的生物制药公司。该公司在血浆衍生物和疫苗的开发与生产方面拥有超过半个世纪的经验，并通过2024年成功进入美国市场的Alyglo®（静脉注射免疫球蛋白G）扩展其全球影响力。In line with its mission to meet the demands of future healthcare, GC Biopharma continues to drive innovation by leveraging its core R&D capabilities in engineering of proteins, mRNAs, and lipid nanoparticle (LNP) drug delivery platform to develop therapeutics for the field of rare disease as well as I&I (Immunology & Inflammation). 为了满足未来医疗保健需求的使命，GC Biopharma继续通过其在蛋白质、mRNA和脂质纳米颗粒（LNP）药物递送平台工程方面的核心研发能力推动创新，开发罕见病以及免疫学与炎症（I&I）领域的治疗药物。To learn more about the company, visit https://www.gcbiopharma.com/eng/. 要了解更多关于该公司的信息，请访问 https://www.gcbiopharma.com/eng/。This press release may contain biopharmaceuticals in forward-looking statements, which express the current beliefs and expectations of GC Biopharma's management. Such statements do not represent any guarantee by GC Biopharma or its management of future performance and involve known and unknown risks, uncertainties, and other factors. 本新闻稿中的前瞻性声明可能包含生物制药内容，表达GC Biopharma管理层当前的信念和期望。此类声明不代表GC Biopharma或其管理层对未来的业绩做出任何保证，并且涉及已知和未知的风险、不确定性及其他因素。GC Biopharma undertakes no obligation to update or revise any forward-looking statement contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule.. GC Biopharma 不承担更新或修改本新闻稿中包含的任何前瞻性声明或其可能作出的任何其他前瞻性声明的义务，除非法律或证券交易所规则要求。GC Biopharma Contacts (Media) GC生物制药联系人（媒体）Sohee Kim 金素熙shkim20@gccorp.com shkim20@gccorp.comYelin Jun 岳麟俊yelin@gccorp.com 叶林@gccorp.comYoonjae Na 罗允载yjy6520@gccorp.com yjy6520@gccorp.comSource:prnewswire.com 来源：prnewswire.com

2025-12-08

·PRNewswire

GC Biopharma Ships First Doses of World's First Recombinant Anthrax Vaccine, 'BARYTHRAX inj.'

- First anthrax vaccine developed using recombinant DNA technology - Annual production capacity of up to 10 million doses at GC Biopharma's facility YONGIN, South Korea, Dec. 8, 2025 /PRNewswire/ -- GC Biopharma (006280.KS), a leading global biopharmaceutical company, today announced the first shipment of BARYTHRAX inj., the world's first recombinant anthrax vaccine. The product, jointly developed by the Korea Disease Control and Prevention Agency (KDCA) and GC Biopharma, was granted regulatory approval in April as Korea's 39th locally developed new drug. The initial supply will be delivered to the KDCA for national stockpiling, supporting public health preparedness against biological threats, including potential bioterrorism. BARYTHRAX inj. is the first anthrax vaccine globally to be developed using recombinant protein technology. Unlike conventional vaccines that use live attenuated or avirulent strain of Bacillus anthracis, BARYTHRAX inj. is based solely on the purified Protective Antigen (PA) protein, a principal component of the anthrax toxin. Clinical studies showed that BARYTHRAX inj. induces neutralizing antibodies that meet the predefined immunogenicity thresholds. This result supports its potential to effectively protect individuals in the event of anthrax exposure. Furthermore, the safety assessment confirmed that the primary adverse events reported in the BARYTHRAX inj. group —such as injection-site pain, myalgia, and fatigue —were generally mild and temporary. No acute adverse reactions or deaths occurred, proving the vaccine's strong safety profile. Manufacturing is carried out at GC Biopharma's advanced Hwasun facility in Korea, which can produce up to 10 million doses annually sufficient to immunize approximately 2.5 million people based on a four-dose regimen. The vaccine is also designed for rapid, scalable production in emergency scenarios. "Delivering the world's first recombinant anthrax vaccine marks a significant step forward in national biosecurity," said Eun-Chul Huh, CEO of GC Biopharma. "We remain committed to supporting national biodefense and advancing vaccine security through innovation and strategic partnerships." About GC Biopharma GC Biopharma (formerly known as Green Cross Corporation) is a biopharmaceutical company headquartered in Yong-in, South Korea. The company has over half a century of experience in the development and manufacturing of plasma derivatives and vaccines, and is expanding its global presence with successful US market entry of Alyglo® (intravenous immunoglobulin G) in 2024. In line with its mission to meet the demands of future healthcare, GC Biopharma continues to drive innovation by leveraging its core R&D capabilities in engineering of proteins, mRNAs, and lipid nanoparticle (LNP) drug delivery platform to develop therapeutics for the field of rare disease as well as I&I (Immunology & Inflammation). To learn more about the company, visit This press release may contain biopharmaceuticals in forward-looking statements, which express the current beliefs and expectations of GC Biopharma's management. Such statements do not represent any guarantee by GC Biopharma or its management of future performance and involve known and unknown risks, uncertainties, and other factors. GC Biopharma undertakes no obligation to update or revise any forward-looking statement contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. GC Biopharma Contacts (Media) Sohee Kim [email protected] Yelin Jun [email protected] Yoonjae Na [email protected] SOURCE GC Biopharma 21% more press release views with Request a Demo

疫苗上市批准

100 项与 Immune globulin (GC Pharma) 相关的药物交易

登录后查看更多信息

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
原发性免疫缺陷疾病	美国	GC Biopharma Corp.	2023-12-15
格林-巴利综合征	韩国	Green Cross Holdings Corp.	2013-09-18
粘膜皮肤淋巴结综合征	韩国	Green Cross Holdings Corp.	2013-08-21
感染	韩国	Green Cross Holdings Corp.	2013-08-15
丙种球蛋白缺乏血症	韩国	Green Cross Holdings Corp.	2013-08-14

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
原发性T细胞免疫缺陷	申请上市	美国	Green Cross Holdings Corp.	2015-11-08
免疫性血小板减少症	临床3期	韩国	Green Cross Co., Ltd.	2014-06-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


FDA 人工标引	N/A	原发性免疫缺陷疾病	33	ALYGLO	繭憲廠積醖蓋蓋壓醖製(獵鏇襯網壓選觸壓願網) = 憲顧壓蓋糧鬱淵鏇獵鹹夢艱衊廠鹹夢鹽製鏇構 (鏇淵鏇衊襯鹹鑰鏇襯網 ) 更多	积极	2023-12-15
NCT02783482 (CTgov)	临床3期	原发性免疫缺陷疾病	49	GC5107 (28-day Schedule)	選鹽餘醖淵鏇齋繭鹹簾 = 構醖範顧鹹糧襯簾夢簾構壓鬱醖鹽鏇餘製襯築 (衊鏇淵窪壓夢製壓餘蓋, 蓋衊鬱窪淵選鹹積衊襯 ~ 壓鑰積鹽夢鑰醖襯齋鹽) 更多	-	2022-10-28
NCT02783482 (CTgov)	临床3期	原发性免疫缺陷疾病	49	GC5107 (21-day Schedule)	選鹽餘醖淵鏇齋繭鹹簾 = 鹹壓廠製鏇艱醖鬱齋顧構壓鬱醖鹽鏇餘製襯築 (衊鏇淵窪壓夢製壓餘蓋, 廠襯蓋糧蓋淵範積衊夢 ~ 窪鹽鬱簾廠醖窪壓淵選) 更多	-	2022-10-28
NCT02783482 (Pubmed \| Front Immunol) 人工标引	临床3期	原发性免疫缺陷疾病	49	GC5107	構艱獵夢齋糧簾範願艱(獵襯獵選蓋衊襯艱顧齋) = acute serious bacterial infection 觸齋製醖製鹹艱網淵製 (窪廠鹽壓夢顧醖鹽艱範 )	积极	2021-07-08
NCT02063789 (Pubmed \| Eur Spine J \| J Korean Med Sci) 人工标引	临床3期	免疫性血小板减少症	81	IVIg-SN	醖選壓簾淵夢製鹽淵獵(築獵築觸衊壓觸膚壓遞) = 願襯顧選鹹構蓋網艱膚糧製鑰鏇構餘壓廠鑰窪 (觸齋餘鬱選製膚遞艱憲, 8.40) 更多	积极	2018-04-24